Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O43488
UPID:
ARK72_HUMAN
Alternative names:
AFB1 aldehyde reductase 1; Aldoketoreductase 7; Succinic semialdehyde reductase
Alternative UPACC:
O43488; O75749; Q5TG63
Background:
Aflatoxin B1 aldehyde reductase member 2, also known as AFB1 aldehyde reductase 1, Aldoketoreductase 7, and Succinic semialdehyde reductase, plays a pivotal role in cellular defense mechanisms. It catalyzes the NADPH-dependent reduction of various aldehydes, including succinic semialdehyde to gamma-hydroxybutyrate (GHB), and exhibits broad substrate specificity. This enzyme is instrumental in detoxifying harmful substances like aflatoxin B1, a potent hepatocarcinogen, by converting it into less toxic forms.
Therapeutic significance:
Understanding the role of Aflatoxin B1 aldehyde reductase member 2 could open doors to potential therapeutic strategies.